Loading stock data…
IQVIA Holdings Inc. provides clinical research services (IQV)
$193.28+2.14 (+1.12%)
Market ClosedLast close Jun 29
IQVIA Holdings Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IQVIA Holdings Inc. in the Healthcare sector is trading at $193.28 with a market capitalization of $29.7B. Wall Street consensus targets $225.47 (19 analysts), implying a +16.7% move over the next 12 months. The stock is currently 22% below its 52-week high of $247.05, remaining 1.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +16.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.15B↓ | $4.36B↑ | $4.10B↑ | $4.02B↑ | $3.83B |
| Gross Profit | $1.35B↓ | $1.44B↑ | $1.37B↑ | $1.32B↑ | $1.30B |
| Operating Income | $565.00M↓ | $651.00M↑ | $573.00M↑ | $538.00M↑ | $525.00M |
| Net Income | $274.00M↓ | $514.00M↑ | $331.00M↑ | $266.00M↑ | $249.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Techno...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.71B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.26%
Volume
Today's trading volume
1.09M
Recent News
Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core Data‑Driven Pharma Enablement Story?
In recent days, IQVIA Holdings has been in focus after commentary underscored ongoing growth challenges, with revenue increases lagging peers and constant-currency trends pointing to softer demand and pressure on market share. This underlines a tension between IQVIA’s broad role in enabling pharmaceutical development and commercialization and the current struggle to convert that position into stronger growth momentum. Next, we’ll examine how these ongoing growth challenges and softer demand...
1 Healthcare Stock with Impressive Fundamentals and 2 We Turn Down
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 5.2% gain for healthcare stocks has fallen short of the S&P 500’s 8.5% rise.
How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?
Despite underperforming its industry peers over the past year, analysts remain highly bullish on Charles River Laboratories' long-term prospects.
1 of Wall Street’s Favorite Stocks on Our Buy List and 2 We Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Morgan Stanley sees writing on wall for key drug research stocks
Wall Street just split sharply on two stocks in the same industry. On Wednesday, June 17, Morgan Stanley upgraded Charles River Laboratories (CRL) to Overweight and downgraded IQVIA Holdings (IQV) to Equal-weight. The twist: IQVIA is buying lab assets that Charles River agreed to sell earlier this ...